Back to search results

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Pancreatic Neoplasm · Colorectal Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • HonorHealth, Scottsdale, Arizona, United States

  • University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States

  • NYU Langone Health - Long Island, Mineola, New York, United States

  • New York University (NYU) Clinical Cancer Center, New York, New York, United States

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio, United States

  • The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

  • START Mountain Region, West Valley City, Utah, United States

  • Cancer Research SA, Adelaide, Australia

  • Icon Cancer Centre South Brisbane, QLD, Australia

  • Centre Leon Berard, Lyon, France

  • Institut de Cancerologie de l'Ouest - site St-Herblain, Saint-Herblain, France

  • Oncopole Claudius Regaud, Toulouse, France

  • Humanitas San Pio X, Milan, Italy

  • Istituto Europeo di Oncologia, Milan, Italy

  • Shizuoka Cancer Center, Shizuoka, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Cancer Institute Hospital of JFCR, Tokyo, Japan

  • National Cancer Center, Goyang-si Gyeonggi-do, South Korea

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

  • Hospital Universitario 12 de Octubre, Madrid, Spain

  • Hospital Clinico Universitario de Valencia, Valencia, Spain

Study leads

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Study Director

    Eli Lilly and Company

View source on ClinicalTrials.gov(opens in a new tab)